Efavaleukin alfa Biosimilar – Anti-TNFRSF18 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2035; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Efavaleukin alfa Biosimilar, also known as Anti-TNFRSF18 fusion protein, is a novel therapeutic antibody that has shown promising results in treating various autoimmune diseases and cancers. This biosimilar is a recombinant fusion protein that is designed to mimic the activity of the natural cytokine, Efavaleukin alfa, which plays a crucial role in regulating the immune response. In this article, we will discuss the structure, activity, and potential applications of Efavaleukin alfa Biosimilar in detail.
Efavaleukin alfa Biosimilar is a fusion protein that is composed of two key components – the extracellular domain of the human TNFRSF18 receptor and the Fc region of human IgG1 antibody. The extracellular domain of TNFRSF18 receptor is responsible for binding to its ligand, Efavaleukin alfa, while the Fc region of IgG1 provides stability and extended half-life to the fusion protein.
The fusion protein is produced through recombinant DNA technology, where the gene encoding for the extracellular domain of TNFRSF18 is fused with the gene encoding for the Fc region of IgG1. This fusion protein is then expressed in a mammalian cell system, resulting in a highly purified and biologically active protein.
As mentioned earlier, Efavaleukin alfa Biosimilar mimics the activity of the natural cytokine, Efavaleukin alfa, which is a member of the TNF superfamily. Efavaleukin alfa plays a key role in regulating the immune response by binding to its receptor, TNFRSF18, which is expressed on various immune cells such as T cells, B cells, and dendritic cells.
By binding to TNFRSF18, Efavaleukin alfa can modulate the activity of these immune cells, leading to a decrease in inflammation and an increase in immune tolerance. This mechanism of action makes Efavaleukin alfa Biosimilar a potential therapeutic option for various autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
In addition to its immunomodulatory effects, Efavaleukin alfa Biosimilar has also shown anti-tumor activity. This is due to its ability to induce apoptosis (cell death) in certain cancer cells, as well as enhance the activity of immune cells against tumors.
Based on its structure and activity, Efavaleukin alfa Biosimilar has potential applications in various therapeutic areas. Some of the key applications of this biosimilar include:
ProteoGenix catalogue number PX-TA2035. For research use only.
Target: Efavaleukin alfa Biosimilar – Anti-TNFRSF18 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Efavaleukin alfa Biosimilar – Anti-TNFRSF18 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
